Beta-defensin 110

Also known as: Beta-defensin 10, Beta-defensin 11, Beta-defensin 111, Defensin, beta 110, Defensin, beta 111, DEFB110, Q30KQ9

Beta-defensin 110 (DEFB110) is a member of the beta-defensin family of antimicrobial peptides, characterized by a conserved six-cysteine motif that forms three disulfide bridges. Its proposed mechanism of action involves direct interaction with bacterial cell membranes, leading to membrane disruption and subsequent microbial killing. As a cationic peptide, it is thought to preferentially bind to negatively charged bacterial membranes, inducing pore formation or membrane destabilization, though specific molecular targets remain uncharacterized. Currently, beta-defensin 110 is classified as an experimental peptide with no published PubMed-indexed research studies. Its functional characterization is inferred primarily from sequence homology to other beta-defensins, such as DEFB1 and DEFB4, which exhibit broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria. No in vitro, in vivo, or clinical data are available to confirm its specific antimicrobial spectrum, potency, or physiological role. Given the absence of direct experimental evidence, the clinical relevance of beta-defensin 110 remains undefined. It has not been investigated in any therapeutic or diagnostic context, and no safety, efficacy, or pharmacokinetic data exist. Further research is required to validate its proposed antibacterial activity and explore potential applications in infectious disease or immune modulation. For research purposes only — not medical advice.

Key data

Mechanism of action

Has antibacterial activity

Frequently asked questions

Related peptides